Hind Selman-Housein BK. Bequet-Romero M, Sánchez RJ, de la Torre PJ, Godínez DD, Ayala ÁM

Language: Spanish
References: 6
Page: 123-128
PDF size: 62.91 Kb.

ABSTRACT

We present case report of 75 years old patient diagnose in august 2013 of metastatic renal carcinoma. The patient was included in clinical trial. A vaccine candidate for solid tumors with VEGF as target was administrated. It is describe long-term clinical evolution and immune response to vaccination after 29 months of immunizations every four weeks. Results are discuses.

REFERENCES

1. Gavilondo JV, Hernández F, Ayala M, de la Torre AV, de la Torre J, Morera Y, et al. Specific active immunoterapy with a VEGF vaccine in patients with advance solid tumors. Results of CENTAURO antigen doses escalation phase I clinical trial. Vaccine. 2014;32:2241-50.

2. Schlom J. Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst. 2012;104:599-613.

3. Silk AW, Finn OJ. Cancer vaccines: a promising cancer therapy against all odds. Fut Oncol. 2007;3:299-306.

4. American Cancer Society. National Cancer Data Base; 2014.

5. Escudier B, Pluzanska A, Koralewski P. For the AVOREN trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet. 2007;370:2103-11.

6. Motzer RJ, Hutson TE, Tomczak P. Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med. 2007;356:115-24.